Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2018’, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections

- The report reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections therapeutics and enlists all their major and minor projects

- The report assesses Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Debiopharm International SA

Destiny Pharma Plc

Sealife PHARMA GMBH

Tetraphase Pharmaceuticals Inc

Debiopharm International SA

Destiny Pharma Plc

Sealife PHARMA GMBH

Tetraphase Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview

Methicillin-Susceptible Staphylococcus aureus (MSSA ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development

Debiopharm International SA

Destiny Pharma Plc

Sealife PHARMA GMBH

Tetraphase Pharmaceuticals Inc

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drug Profiles

afabicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exeporfinium chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HY-133 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAI-108 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLP-0904 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLP-0905 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DNA Gyrase and DNA Topoisomerase IV for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

targocil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-271 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Tables

Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA, H2 2018

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Destiny Pharma Plc, H2 2018

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sealife PHARMA GMBH, H2 2018

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2018

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, H2 2018

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Figures

Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports